Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity

Rohrbach,Timothy D.; Jarboe,John S.; Anderson,Joshua C.; Trummell,Hoa Q.; Hicks,Patricia H.; Weaver,Alice N.; Yang,Eddy S.; Oster,Robert A.; Deshane,Jessy S.; Steele,Chad; Siegal,Gene P.; Bonner,James A.; Willey,Christopher D.

doi:10.3892/ijo.2014.2799

Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivity

Authors:
- Timothy D. Rohrbach
- John S. Jarboe
- Joshua C. Anderson
- Hoa Q. Trummell
- Patricia H. Hicks
- Alice N. Weaver
- Eddy S. Yang
- Robert A. Oster
- Jessy S. Deshane
- Chad Steele
- Gene P. Siegal
- James A. Bonner
- Christopher D. Willey
View Affiliations

Affiliations: Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL, USA, Division of Preventive Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA, Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA
Published online on: December 17, 2014 https://doi.org/10.3892/ijo.2014.2799
Pages: 1079-1088

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of cancer related deaths. Common molecular drivers of lung cancer are mutations in receptor tyrosine kinases (RTKs) leading to activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pro-growth, pro-survival signaling pathways. Myristoylated alanine rich C-kinase substrate (MARCKS) is a protein that has the ability to mitigate this signaling cascade by sequestering the target of PI3K, phosphatidylinositol (4,5)-bisphosphate (PIP2). As such, MARCKS has been implicated as a tumor suppressor, though there is some evidence that MARCKS may be tumor promoting in certain cancer types. Since the MARCKS function depends on its phosphorylation status, which impacts its subcellular location, MARCKS role in cancer may depend highly on the signaling context. Currently, the importance of MARCKS in lung cancer biology is limited. Thus, we investigated MARCKS in both clinical specimens and cell culture models. Immunohistochemistry scoring of MARCKS protein expression in a diverse lung tumor tissue array revealed that the majority of squamous cell carcinomas stained positive for MARCKS while other histologies, such as adenocarcinomas, had lower levels. To study the importance of MARCKS in lung cancer biology, we used inducible overexpression of wild-type (WT) and non-phosphorylatable (NP)-MARCKS in A549 lung cancer cells that had a low level of endogenous MARCKS. We found that NP-MARCKS expression, but not WT-MARCKS, enhanced the radiosensitivity of A549 cells in part by inhibiting DNA repair as evidenced by prolonged radiation-induced DNA double strand breaks. We confirmed the importance of MARCKS phosphorylation status by treating several lung cancer cell lines with a peptide mimetic of the phosphorylation domain, the effector domain (ED), which effectively attenuated cell growth as measured by cell index. Thus, the MARCKS ED appears to be an important target for lung cancer therapeutic development.

View Figures

View References

1	Bickeboller M, Tagscherer KE, Kloor M, et al: Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival. Oncogene. 24–March;2014.(Epub ahead of print). View Article : Google Scholar
2	Brooks G, Brooks SF and Goss MW: MARCKS functions as a novel growth suppressor in cells of melanocyte origin. Carcinogenesis. 17:683–689. 1996. View Article : Google Scholar : PubMed/NCBI
3	Jarboe JS, Anderson JC, Duarte CW, et al: MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res. 18:3030–3041. 2012. View Article : Google Scholar : PubMed/NCBI
4	Li T, Li D, Sha J, Sun P and Huang Y: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 383:280–285. 2009. View Article : Google Scholar : PubMed/NCBI
5	Masaki T, Tokuda M, Yoshida S, et al: Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol. 26:661–671. 2005.PubMed/NCBI
6	Browne BC, Hochgräfe F, Wu J, et al: Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. FEBS J. 280:5237–5257. 2013. View Article : Google Scholar : PubMed/NCBI
7	Techasen A, Loilome W, Namwat N, et al: Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. Cancer Sci. 101:658–665. 2010. View Article : Google Scholar : PubMed/NCBI
8	Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ and Kurzrock R: Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 6:1601–1612. 2011. View Article : Google Scholar : PubMed/NCBI
9	Newton AC: Lipid activation of protein kinases. J Lipid Res. 50(Suppl): S266–S271. 2009. View Article : Google Scholar :
10	Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
11	Ellena JF, Burnitz MC and Cafiso DS: Location of the myristoylated alanine-rich C-kinase substrate (MARCKS) effector domain in negatively charged phospholipid bicelles. Biophys J. 85:2442–2448. 2003. View Article : Google Scholar : PubMed/NCBI
12	Wang J, Gambhir A, Hangyas-Mihalyne G, Murray D, Golebiewska U and McLaughlin S: Lateral sequestration of phosphatidylinositol 4,5-bisphosphate by the basic effector domain of myristoylated alanine-rich C kinase substrate is due to nonspecific electrostatic interactions. J Biol Chem. 277:34401–34412. 2002. View Article : Google Scholar : PubMed/NCBI
13	Tanabe A, Kamisuki Y, Hidaka H, Suzuki M, Negishi M and Takuwa Y: PKC phosphorylates MARCKS Ser159 not only directly but also through RhoA/ROCK. Biochem Biophys Res Commun. 345:156–161. 2006. View Article : Google Scholar : PubMed/NCBI
14	Thelen M, Rosen A, Nairn AC and Aderem A: Regulation by phosphorylation of reversible association of a myristoylated protein kinase C substrate with the plasma membrane. Nature. 351:320–322. 1991. View Article : Google Scholar : PubMed/NCBI
15	Clarke PR, Siddhanti SR, Cohen P and Blackshear PJ: Okadaic acid-sensitive protein phosphatases dephosphorylate MARCKS, a major protein kinase C substrate. FEBS Lett. 336:37–42. 1993. View Article : Google Scholar : PubMed/NCBI
16	Stumpo DJ, Graff JM, Albert KA, Greengard P and Blackshear PJ: Molecular cloning, characterization, and expression of a cDNA encoding the ‘80- to 87-kDa’ myristoylated alanine-rich C kinase substrate: a major cellular substrate for protein kinase C. Proc Natl Acad Sci USA. 86:4012–4016. 1989. View Article : Google Scholar
17	Hanada S, Kakehashi A, Nishiyama N, et al: Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma. Cancer Biomark. 13:289–298. 2013.PubMed/NCBI
18	Chen CH, Thai P, Yoneda K, Adler KB, Yang PC and Wu R: A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis. Oncogene. 33:3696–3706. 2013. View Article : Google Scholar : PubMed/NCBI
19	Graff JM, Rajan RR, Randall RR, Nairn AC and Blackshear PJ: Protein kinase C substrate and inhibitor characteristics of peptides derived from the myristoylated alanine-rich C kinase substrate (MARCKS) protein phosphorylation site domain. J Biol Chem. 266:14390–14398. 1991.PubMed/NCBI
20	Solly K, Wang X, Xu X, Strulovici B and Zheng W: Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol. 2:363–372. 2004. View Article : Google Scholar : PubMed/NCBI
21	Nam HY, Han MW, Chang HW, et al: Radioresistant cancer cells can be conditioned to enter senescence by mTOR inhibition. Cancer Res. 73:4267–4277. 2013. View Article : Google Scholar : PubMed/NCBI
22	Jarboe JS, Jaboin JJ, Anderson JC, et al: Kinomic profiling approach identifies Trk as a novel radiation modulator. Radiother Oncol. 103:380–387. 2012. View Article : Google Scholar : PubMed/NCBI
23	Tu T, Thotala D, Geng L, Hallahan DE and Willey CD: Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res. 68:2861–2869. 2008. View Article : Google Scholar : PubMed/NCBI
24	Yang ES, Wang H, Jiang G, et al: Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK-dependent repair in mice. J Clin Invest. 119:1124–1135. 2009. View Article : Google Scholar : PubMed/NCBI
25	Nowsheen S, Bonner JA and Yang ES: The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol. 99:331–338. 2011. View Article : Google Scholar : PubMed/NCBI
26	Yang ES, Nowsheen S, Wang T, Thotala DK and Xia F: Glycogen synthase kinase 3beta inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons. Neuro Oncol. 13:459–470. 2011. View Article : Google Scholar : PubMed/NCBI
27	Gao J, Aksoy BA, Dogrusoz U, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBio-Portal. Sci Signal. 6:pl12013.
28	Cerami E, Gao J, Dogrusoz U, et al: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
29	Ohmori S, Sakai N, Shirai Y, et al: Importance of protein kinase C targeting for the phosphorylation of its substrate, myristoylated alanine-rich C-kinase substrate. J Biol Chem. 275:26449–26457. 2000. View Article : Google Scholar : PubMed/NCBI
30	Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc. 1:2315–2319. 2006. View Article : Google Scholar
31	Chen X and Rotenberg SA: PhosphoMARCKS drives motility of mouse melanoma cells. Cell Signal. 22:1097–1103. 2010. View Article : Google Scholar : PubMed/NCBI
32	Disatnik MH, Boutet SC, Pacio W, et al: The bi-directional translocation of MARCKS between membrane and cytosol regulates integrin-mediated muscle cell spreading. J Cell Sci. 117:4469–4479. 2004. View Article : Google Scholar : PubMed/NCBI
33	Yarmola EG, Edison AS, Lenox RH and Bubb MR: Actin filament cross-linking by MARCKS: characterization of two actin-binding sites within the phosphorylation site domain. J Biol Chem. 276:22351–22358. 2001. View Article : Google Scholar : PubMed/NCBI
34	Kalwa H and Michel T: The MARCKS protein plays a critical role in phosphatidylinositol 4,5-bisphosphate metabolism and directed cell movement in vascular endothelial cells. J Biol Chem. 286:2320–2330. 2011. View Article : Google Scholar :